Cargando…

The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau

BACKGROUND: Providing an early, additional measles vaccine (MV) at 4.5 months of age has been shown to reduce child mortality in low-income countries. We studied the effects on growth at 9 and 24 months of age. METHODS: A randomized controlled trial was conducted in Guinea-Bissau from 2003–2007 incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasmussen, S. M., Biering-Sørensen, S., Byberg, S., Andersen, A., Bjerregaard-Andersen, M., Rodrigues, A., Benn, C. S., Martins, C. L., Aaby, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135799/
https://www.ncbi.nlm.nih.gov/pubmed/27912735
http://dx.doi.org/10.1186/s12887-016-0738-z
_version_ 1782471610423312384
author Rasmussen, S. M.
Biering-Sørensen, S.
Byberg, S.
Andersen, A.
Bjerregaard-Andersen, M.
Rodrigues, A.
Benn, C. S.
Martins, C. L.
Aaby, P.
author_facet Rasmussen, S. M.
Biering-Sørensen, S.
Byberg, S.
Andersen, A.
Bjerregaard-Andersen, M.
Rodrigues, A.
Benn, C. S.
Martins, C. L.
Aaby, P.
author_sort Rasmussen, S. M.
collection PubMed
description BACKGROUND: Providing an early, additional measles vaccine (MV) at 4.5 months of age has been shown to reduce child mortality in low-income countries. We studied the effects on growth at 9 and 24 months of age. METHODS: A randomized controlled trial was conducted in Guinea-Bissau from 2003–2007 including 6,648 children. Children were randomized 1:1:1 to receive Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group A), no vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months (group B), or no vaccine at 4.5 months and Schwarz measles vaccine at 9 months (group C) Data on anthropometrics were obtained at enrolment at 4.5 months of age and again at 9 and 24 months of age. Analyses were stratified by sex, season of enrolment, and neonatal vitamin A supplementation (NVAS) status, as all these factors have been shown to modify the effect of early MV on mortality. RESULTS: Overall there was no effect of early MV on anthropometry at 9 months. At 24 months children who had received early MV had a significantly larger mid-upper-arm-circumference (MUAC/in cm) (Difference = 0.08; 95% CI (0.02;0.14)) compared with children in the control group; this effect was most pronounced among girls (0.12 (0.03;0.20)). The effect of early MV on MUAC remained significant in the dry season and in girls who received placebo rather than NVAS. CONCLUSION: Early MV was associated with a larger MUAC particularly in girls. These results indicate that a two-dose measles vaccination schedule might not only reduce child mortality but also improve growth. TRIAL REGISTRATION: ClinicalTrials.gov NCT00168558. Registered September 9, 2005, retrospectively registered ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12887-016-0738-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5135799
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51357992016-12-15 The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau Rasmussen, S. M. Biering-Sørensen, S. Byberg, S. Andersen, A. Bjerregaard-Andersen, M. Rodrigues, A. Benn, C. S. Martins, C. L. Aaby, P. BMC Pediatr Research Article BACKGROUND: Providing an early, additional measles vaccine (MV) at 4.5 months of age has been shown to reduce child mortality in low-income countries. We studied the effects on growth at 9 and 24 months of age. METHODS: A randomized controlled trial was conducted in Guinea-Bissau from 2003–2007 including 6,648 children. Children were randomized 1:1:1 to receive Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group A), no vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months (group B), or no vaccine at 4.5 months and Schwarz measles vaccine at 9 months (group C) Data on anthropometrics were obtained at enrolment at 4.5 months of age and again at 9 and 24 months of age. Analyses were stratified by sex, season of enrolment, and neonatal vitamin A supplementation (NVAS) status, as all these factors have been shown to modify the effect of early MV on mortality. RESULTS: Overall there was no effect of early MV on anthropometry at 9 months. At 24 months children who had received early MV had a significantly larger mid-upper-arm-circumference (MUAC/in cm) (Difference = 0.08; 95% CI (0.02;0.14)) compared with children in the control group; this effect was most pronounced among girls (0.12 (0.03;0.20)). The effect of early MV on MUAC remained significant in the dry season and in girls who received placebo rather than NVAS. CONCLUSION: Early MV was associated with a larger MUAC particularly in girls. These results indicate that a two-dose measles vaccination schedule might not only reduce child mortality but also improve growth. TRIAL REGISTRATION: ClinicalTrials.gov NCT00168558. Registered September 9, 2005, retrospectively registered ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12887-016-0738-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-12-03 /pmc/articles/PMC5135799/ /pubmed/27912735 http://dx.doi.org/10.1186/s12887-016-0738-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rasmussen, S. M.
Biering-Sørensen, S.
Byberg, S.
Andersen, A.
Bjerregaard-Andersen, M.
Rodrigues, A.
Benn, C. S.
Martins, C. L.
Aaby, P.
The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau
title The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau
title_full The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau
title_fullStr The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau
title_full_unstemmed The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau
title_short The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau
title_sort effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in guinea-bissau
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135799/
https://www.ncbi.nlm.nih.gov/pubmed/27912735
http://dx.doi.org/10.1186/s12887-016-0738-z
work_keys_str_mv AT rasmussensm theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT bieringsørensens theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT bybergs theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT andersena theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT bjerregaardandersenm theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT rodriguesa theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT benncs theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT martinscl theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT aabyp theeffectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT rasmussensm effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT bieringsørensens effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT bybergs effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT andersena effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT bjerregaardandersenm effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT rodriguesa effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT benncs effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT martinscl effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau
AT aabyp effectofearlymeaslesvaccinationat45monthsofageongrowthat9and24monthsofageinarandomizedtrialinguineabissau